Cited by 319CRISPR and Genetic EngineeringVirus-based gene therapy researchHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

CRISPR/Cas9 genome editing in human hematopoietic stem cells.

Open access

Bak, Rasmus O, Dever, Daniel P, Porteus, Matthew H·2018·Nature Protocols

DOI 10.1038/nprot.2017.143PMC PMC5826598

Open this paper in CoChat — free account

Abstract

Genome editing via homologous recombination (HR) (gene targeting) in human hematopoietic stem cells (HSCs) has the power to reveal gene-function relationships and potentially transform curative hematological gene and cell therapies. However, there are no comprehensive and reproducible protocols for targeting HSCs for HR. Herein, we provide a detailed protocol for the production, enrichment, and in vitro and in vivo analyses of HR-targeted HSCs by combining CRISPR/Cas9 technology with the use of rAAV6 and flow cytometry. Using this protocol, researchers can introduce single-nucleotide changes into the genome or longer gene cassettes with the precision of genome editing. Along with our troubleshooting and optimization guidelines, researchers can use this protocol to streamline HSC genome editing at any locus of interest. The in vitro HSC-targeting protocol and analyses can be completed in 3 weeks, and the long-term in vivo HSC engraftment analyses in immunodeficient mice can be achieved in 16 weeks. This protocol enables manipulation of genes for investigation of gene functions during hematopoiesis, as well as for the correction of genetic mutations in HSC transplantation-based therapies for diseases such as sickle cell disease, β-thalassemia, and primary immunodeficiencies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nprot.2017.143

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Trypan Blue Exclusion Test of Cell Viability
Strober, W. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.ima03bs111 · Cited by 2,631
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature reviews. Immunology · doi:10.1038/nri2017 · Cited by 1,393
Trypan Blue Exclusion Test of Cell Viability
Strober, W. (1997) · Current Protocols in Immunology · doi:10.1002/0471142735.ima03bs21 · Cited by 1,349
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citation

Flagged first, then by citations

Show all 57 references

1 of the 57 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 317

Enrichment strategies to enhance genome editing
Mikkelsen, N. S., & Bak, R. O. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00943-1 · Cited by 32
Self-citation
Efficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells
Tran, N. T., Sommermann, T. G., Graf, R., Trombke, J., Pempe, J., Petsch, K., Kühn, R., Rajewsky, K., & Chu, V. T. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.065 · Cited by 34
DL-CRISPR: A Deep Learning Method for Off-Target Activity Prediction in CRISPR/Cas9 With Data Augmentation
Zhang, Y., Long, Y., Yin, R., & Kwoh, C. K. (2020) · IEEE Access · doi:10.1109/access.2020.2989454 · Cited by 31
Gene Editing for the Treatment of Primary Immunodeficiency Diseases
Rai, R., Thrasher, A. J., & Cavazza, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.185 · Cited by 30
CRISPR-edited megakaryocytes for rapid screening of platelet gene functions
Montenont, E., Bhatlekar, S., Jacob, S. P., Kosaka, Y., Manne, B. K., Lee, O., Parra‐Izquierdo, I., Tugolukova, E. A., Tolley, N. D., Rondina, M. T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004112 · Cited by 31
Cas9‐Cleavage Sequences in Size‐Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells
Jing, R., Jiao, P., Chen, J., Meng, X., Wu, X., Duan, Y., Shang, K., Qian, L., Huang, Y., Liu, J., et al. (2021) · Small Methods · doi:10.1002/smtd.202100071 · Cited by 32
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
Rothemejer, F. H., Lauritsen, N. P., Juhl, A. K., Schleimann, M. H., König, S., Søgaard, O. S., Bak, R. O., & Tolstrup, M. (2023) · Viruses · doi:10.3390/v15010202 · Cited by 31
Self-citation
Recent advances in nanocomposite-based delivery systems for targeted CRISPR/Cas delivery and therapeutic genetic manipulation
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 32
Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice
Leonard, A. K., Yapundich, M., Nassehi, T., Gamer, J., Drysdale, C. M., Haro‐Mora, J. J., Demirci, S., Hsieh, M. M., Uchida, N., & Tisdale, J. F. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.017 · Cited by 30
Biallelic correction of sickle cell disease-derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum-free iPS-sac/erythroid differentiation
Haro‐Mora, J. J., Uchida, N., Demirci, S., Wang, Q., Zou, J., & Tisdale, J. F. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0216 · Cited by 30
The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells
Sharma, R., Dever, D. P., Lee, C. M., Azizi, A., Pan, Y., Camarena, J., Köhnke, T., Bao, G., Porteus, M. H., & Majeti, R. (2021) · Nature Communications · doi:10.1038/s41467-020-20792-y · Cited by 30
Self-citation
Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Ex-Vivo Gene Editing
Dudek, A. M., & Porteus, M. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660302 · Cited by 30
Self-citation
Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus
Chavez, M., Rane, D. A., Chen, X., & Qi, L. S. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01037-x · Cited by 30
Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells
Zhang, Y., Fang, H., Wang, G., Yuan, G., Dong, R., Luo, J., Lyu, Y., Wang, Y., Li, P., Zhou, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44176-0 · Cited by 32
Applications of the CRISPR-Cas system for infectious disease diagnostics
Li, P., Wang, L., Yang, J., Di, L., & Li, J. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1922080 · Cited by 29
PLAG1 dampens protein synthesis to promote human hematopoietic stem cell self-renewal
Chahi, A. K., Belew, M. S., Xu, J., Chen, H. T., Rentas, S., Voisin, V., Krivdova, G., Lechman, E. R., Marhon, S. A., Carvalho, D. D. D., et al. (2022) · Blood · doi:10.1182/blood.2021014698 · Cited by 28
Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair
Webber, B. R., Johnson, M. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., DeFeo, A. P., Mills, L. J., Qiu, X., Rathmann, B., Diers, M. D., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01157-4 · Cited by 29
Advances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Rı́o, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 28
Hematopoietic stem cells retain functional potential and molecular identity in hibernation cultures
Oedekoven, C. A., Belmonte, M., Bode, D., Hamey, F., Shepherd, M. S., Che, J. L. C., Boyd, G., McDonald, C., Belluschi, S., Diamanti, E., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.04.002 · Cited by 24
All Patients With Common Variable Immunodeficiency Disorders (CVID) Should Be Routinely Offered Diagnostic Genetic Testing
Ameratunga, R., Lehnert, K., & Woon, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02678 · Cited by 29
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 27
Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing
Zhang, H., Sun, R., Fei, J., Chen, H., & Lu, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115948 · Cited by 27
Robust CRISPR/Cas9 Genome Editing of the HUDEP-2 Erythroid Precursor Line Using Plasmids and Single-Stranded Oligonucleotide Donors
Moir-Meyer, G., Cheong, P. L., Olijnik, A.-A., Brown, J. M., Knight, S. J. L., King, A. J., Kurita, R., Nakamura, Y., Gibbons, R. J., Higgs, D. R., et al. (2018) · Methods and Protocols · doi:10.3390/mps1030028 · Cited by 24
First Steps toward Uncovering Gene Doping with CRISPR/Cas by Identifying SpCas9 in Plasma via HPLC–HRMS/MS
Paßreiter, A., Thomas, A., Grogna, N., Delahaut, P., & Thevis, M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04445 · Cited by 24
CRISPR knockdown of Kcnq3 attenuates the M-current and increases excitability of NPY/AgRP neurons to alter energy balance
Stincic, T. L., Bosch, M. A., Hunker, A. C., Juarez, B., Connors, A. M., Zweifel, L. S., Rønnekleiv, O. K., & Kelly, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101218 · Cited by 25
High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus–Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells
Allen, D. G., Weiss, L. E., Saguy, A., Rosenberg, M., Iancu, O., Matalon, O., Lee, C. M., Beider, K., Nagler, A., Shechtman, Y., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0128 · Cited by 25
Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 26
CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside
Humbert, O., Samuelson, C., & Kiem, H. (2020) · British Journal of Haematology · doi:10.1111/bjh.16807 · Cited by 27
Gene therapy for primary immunodeficiencies
Fox, T. A., & Booth, C. (2020) · British Journal of Haematology · doi:10.1111/bjh.17269 · Cited by 27
CRISPR-Cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications
Allen, D. G., Knop, O., Itkowitz, B., Kalter, N., Rosenberg, M., Iancu, O., Beider, K., Lee, Y. N., Nagler, A., Somech, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42036-5 · Cited by 25
Designing custom CRISPR libraries for hypothesis-driven drug target discovery
Iyer, V. S., Jiang, L., Shen, Y., Boddul, S. V., Panda, S. K., Kasza, Z., Schmierer, B., & Wermeling, F. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.009 · Cited by 21
Hematopoietic stem cell gene editing and expansion: State-of-the-art technologies and recent applications
Haltalli, M. L. R., Wilkinson, A. C., Rodriguez-Fraticelli, A., & Porteus, M. H. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.399 · Cited by 23
Self-citation
Engineering Mice to Study Human Immunity
Sefik, E., Xiao, T., Chiorazzi, M., Odell, I. D., Zhang, F., Agrawal, K., Micevic, G., & Flavell, R. A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082523-124415 · Cited by 24
The Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell Disease
Desine, S., Hollister, B. M., Abdallah, K. E., Persaud, A., Hull, S. C., & Bonham, V. L. (2020) · AJOB Empirical Bioethics · doi:10.1080/23294515.2020.1818876 · Cited by 23
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities
Foßelteder, J., Pabst, G., Sconocchia, T., Schlacher, A., Auinger, L., Kashofer, K., Beham‐Schmid, C., Trajanoski, S., Waskow, C., Schöll, W., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01848-6 · Cited by 21
Establishment of protocol for preparation of gene-edited bovine ear-derived fibroblasts for somatic cell nuclear transplantation
Ishino, T., Hashimoto, M., Amagasa, M., SAITO, N., Dochi, O., KIRISAWA, R., & Kitamura, H. (2018) · Biomedical Research · doi:10.2220/biomedres.39.95 · Cited by 21
Anti‐Atherogenic Effect of Stem Cell Nanovesicles Targeting Disturbed Flow Sites
Yoon, J., Kim, D., Kang, M., Jang, H., Park, H., Lee, J. B., Yi, S. W., Kim, H., Baek, S., Park, D. B., et al. (2020) · Small · doi:10.1002/smll.202000012 · Cited by 21
Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
Papizan, J. B., Porter, S. N., Sharma, A., & Pruett‐Miller, S. M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200096 · Cited by 21
Advances in CRISPR/Cas gene therapy for inborn errors of immunity
Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., & Li, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111777 · Cited by 21
Pediatric leukemia: Moving toward more accurate models
Milan, T., Canaj, H., Villeneuve, C., Ghosh, A., Barabé, F., Cellot, S., & Wilhelm, B. T. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.05.003 · Cited by 22
Genome-based therapeutic interventions for β-type hemoglobinopathies
Karamperis, K., Tsoumpeli, M. T., Kounelis, F., Koromina, M., Mitropoulou, C., Moutinho, C., & Patrinos, G. P. (2021) · Human Genomics · doi:10.1186/s40246-021-00329-0 · Cited by 20
An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells
Hsu, L.-J., Liu, C., Kuo, M., Shen, C., & Shen, C. (2021) · Biomedicines · doi:10.3390/biomedicines9101323 · Cited by 19
A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection
Dudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
Self-citation
Efficient gene correction of an aberrant splice site in β‐thalassaemia iPSCs by CRISPR/Cas9 and single‐strand oligodeoxynucleotides
Xiong, Z., Xie, Y., Yang, Y., Xue, Y., Wang, D., Lin, S., Chen, D., Lu, D., He, L., Song, B., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14669 · Cited by 20
Recent advances in regenerative medicine
Rajpoot, K., Safavi, M., Sreeharsha, N., & Tekade, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814455-8.00011-6 · Cited by 18
CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy
Meshitsuka, S., Ninomiya, R., Nagamura‐Inoue, T., Okada, T., Futami, M., & Tojo, A. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.09.009 · Cited by 18
Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119
Köhnke, T., Nuno, K. A., Alder, C. C., Gars, E. J., Phan, P., Fan, A. C., & Majeti, R. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0235 · Cited by 23
CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases
Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 20
Orthogonal CRISPR systems for targeted integration and multiplex base editing enable nonviral engineering of allogeneic CAR-T cells
Mikkelsen, N. S., Ravendran, S., Broksø, A. D., Skjelbostad, S. F., Pedersen, M. G., Fang, H., Terkelsen, T., Thomsen, M. K., & Bak, R. O. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.032 · Cited by 18
Self-citation
Selecting for CRISPR-Edited Knock-In Cells
Reuven, N. B., & Shaul, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911919 · Cited by 16
Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders
Allen, D. G., Kalter, N., Rosenberg, M., & Hendel, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051329 · Cited by 18
“Designer babies?!” A CRISPR ‐based learning module for undergraduates built around the CCR5 gene
Pieczynski, J. N., & Kee, H. L. (2020) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.21395 · Cited by 16
Acute myeloid leukemia cell-derived extracellular vesicles carrying microRNA-548ac regulate hematopoietic function via the TRIM28/STAT3 pathway
Zhao, C., Zhao, Y., Zhao, J., Meng, G., Huang, S., Liu, Y., Wang, S., & Qi, L. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00378-6 · Cited by 16
Correcting inborn errors of immunity: From viral mediated gene addition to gene editing
Castiello, M. C., Ferrari, S., & VILLA, A. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101731 · Cited by 16
Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples
Modarai, S., Kanda, S., Bloh, K. M., Opdenaker, L. M., & Kmiec, E. B. (2020) · Gene Therapy · doi:10.1038/s41434-020-00192-z · Cited by 18
In Vivo Studies of Mesenchymal Stem Cells in the Treatment of Meniscus Injury
Dai, T., Pan, Z., & Yin, F. (2021) · Orthopaedic Surgery · doi:10.1111/os.13002 · Cited by 16
BAR-Seq clonal tracking of gene-edited cells
Ferrari, S., Beretta, S., Jacob, A., Cittaro, D., Albano, L., Merelli, I., Naldini, L., & Genovese, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00529-x · Cited by 15
A Curative DNA Code for Hematopoietic Defects
Porteus, M. H., Pavel-Dinu, M., & Pai, S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.002 · Cited by 15
Self-citation
CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells
Rai, R., Steinberg, Z., Romito, M., Zinghirino, F., Hu, Y., White, N., Naseem, A., Thrasher, A. J., Turchiano, G., & Cavazza, A. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.100 · Cited by 14
Platelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis
Gwag, T., Lee, S., Li, Z.-Y., Newcomb, A., Otuagomah, J., Weinman, S., Liang, Y., Zhou, C., & Wang, S. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101019 · Cited by 15
Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells
Salisbury-Ruf, C. T., & Larochelle, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030513 · Cited by 15
Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems
Broksø, A. D., Bendixen, L., Fammé, S., Mikkelsen, K., Jensen, T. I., & Bak, R. O. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.024 · Cited by 14
Self-citation
An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes
Dai, Y., Ignatyeva, N., Xu, H., Wali, R., Toischer, K., Brandenburg, S., Lenz, C., Pronto, J. R. D., Fakuade, F. E., Sossalla, S. T., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321157 · Cited by 13
RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition
Fan, A. C., Nakauchi, Y., Bai, L., Azizi, A., Nuno, K. A., Zhao, F., Köhnke, T., Karigane, D., Hernandez, D. C., Reinisch, A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167053 · Cited by 16
Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells
Luna, S. E., Camarena, J., Hampton, J. P., Majeti, K. R., Charlesworth, C. T., Soupène, E., Selvaraj, S., Jia, K., Sheehan, V., Cromer, M. K., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01222-6 · Cited by 17
Self-citation
AUTS2 disruption causes neuronal differentiation defects in human cerebral organoids through hyperactivation of the WNT/β-catenin pathway
Geng, Z., Tai, Y. T., Wang, Q., & Gao, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-69912-4 · Cited by 14
IL-2 receptor engineering enhances regulatory T cell function suppressed by calcineurin inhibitor
Hirai, T., Lin, P., Ramos, T. L., Simonetta, F., Su, L., Picton, L. K., Baker, J. B., Lohmeyer, J. K., García, K. C., & Negrin, R. S. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17181 · Cited by 13
A culture platform to study quiescent hematopoietic stem cells following genome editing
Shiroshita, K., Kobayashi, H., Watanuki, S., Karigane, D., Sorimachi, Y., Fujita, S., Tamaki, S., Haraguchi, M., Itokawa, N., Aoyama, K., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100354 · Cited by 12
Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering
Lamothe, R. C., Storlie, M. D., Espinosa, D. A., Rudlaff, R. M., Browne, P. J., Liu, J., Rivas, A., Devoto, A. E., Oki, J., Khoubyari, A., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2022.0089 · Cited by 12
β-Thalassemia gene editing therapy: Advancements and difficulties
Hu, J., Zhong, Y., Xu, P., Xin, L., Zhu, X., Jiang, X., Gao, W., Yang, B., & Chen, Y. (2024) · Medicine · doi:10.1097/md.0000000000038036 · Cited by 19
Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells
Sahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19
Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies
Feist, W. N., Luna, S. E., Ben-Efraim, K., Interrante, M. V. F., Amorin, A., Johnston, N. M., Bruun, T. U. J., Utz, A., Ghanim, H. Y., Lesch, B. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58371-8 · Cited by 15
Self-citation
Non‐negative blind deconvolution for signal processing in a CRISPR‐edited iPSC‐cardiomyocyte model of dilated cardiomyopathy
Xu, H., Wali, R., Cheruiyot, C., Bodenschatz, J. F. E., Hasenfuss, G. P., Janshoff, A., Habeck, M., & Ebert, A. (2021) · FEBS Letters · doi:10.1002/1873-3468.14189 · Cited by 13
Gene editing-based targeted integration for correction of Wiskott-Aldrich syndrome
Pille, M., Avila, J. M., Park, S. H., Le, C. Q., Xue, H., Haerynck, F., Saxena, L., Lee, C. M., Shpall, E. J., Bao, G., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101208 · Cited by 11
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias
Fleming, T. J., Antoszewski, M., Lambo, S., Gundry, M. C., Piussi, R., Wahlster, L., Shah, S. B., Reed, F. E., Dong, K. D., Paulo, J. A., et al. (2025) · Blood · doi:10.1182/blood.2025028954 · Cited by 11
Gene therapy for inborn error of immunity – current status and future perspectives
Mudde, A. C. A., & Booth, C. (2022) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000876 · Cited by 10
Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex
de Alencastro, G., Puzzo, F., Pavel-Dinu, M., Zhang, F., Pillay, S., Majzoub, K., Tiffany, M. R., Jang, H., Sheikali, A., Cromer, M. K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.020 · Cited by 11
Self-citation
CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.793010 · Cited by 11
Self-citation
Expanding the cell quantity of CRISPR/Cas9 gene editing by continuous microfluidic electroporation chip
Li, Z., Su, X., Lin, Y., Zhang, A., Zhang, A., Wu, X. T., Xi, J., Li, Q., & Wei, Z. (2024) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2024.108840 · Cited by 10
Defining the vascular niche of human adipose tissue across metabolic states
AlZaim, I., Hassan, M. N., Schröter, M., Mannino, L., Dragicevic, K., Sjogaard, M. B., Festa, J., Dokshokova, L., Weinbrenner, S., Ayllón, B. T., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01475-2 · Cited by 10
Optimized Guide RNA Selection Improves Streptococcus pyogenes Cas9 Gene Editing of Human Hematopoietic Stem and Progenitor Cells
Verhagen, H. J. M. P., Kuijk, C., Rutgers, L., Kokke, A. M., van der Meulen, S. A., van Mierlo, G. J., Voermans, C., & van den Akker, E. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0112 · Cited by 10
The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?
Ellen, O., Ye, S., Nheu, D., Dass, M., Pagnin, M., Öztürk, E., Theotokis, P., Grigoriadis, N., & Petratos, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311112 · Cited by 11
Rare immune diseases paving the road for genome editing-based precision medicine
Pavel-Dinu, M., Borna, Š., & Bacchetta, R. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1114996 · Cited by 10
Genomic Engineering in Human Hematopoietic Stem Cells: Hype or Hope?
Klaver-Flores, S., Zittersteijn, H. A., Canté-Barrett, K., Lankester, A. C., Hoeben, R. C., Gonçalves, M. A. F. V., Pike‐Overzet, K., & Staal, F. J. T. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.615619 · Cited by 10
Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling
Middlezong, W., Stinnett, V., Phan, M., Phan, B., Morsberger, L. A., Klausner, M., Ghabrial, J., DeMetrick, N., Zhu, J., James, T., et al. (2024) · Biomolecules · doi:10.3390/biom14121595 · Cited by 9
Enrichment of transgene integrations by transient CRISPR activation of a silent reporter gene
Mikkelsen, N. S., Hernández, S. S., Jensen, T. I., Schneller, J. L., & Bak, R. O. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.010 · Cited by 9
Self-citation
Efficient delivery of a large-size Cas9-EGFP vector in porcine fetal fibroblasts using a Lonza 4D-Nucleofector system
Liu, W., Wang, X., Liu, R., Liao, Y., Peng, Z., Jiang, H., Jing, Q., & Xing, Y. (2023) · BMC Biotechnology · doi:10.1186/s12896-023-00799-1 · Cited by 9
In situ correction of various β-thalassemia mutations in human hematopoietic stem cells
Yang, Y., He, L., Xie, Y., Zhu, L., Wu, J., Fan, Y., Yang, Y., & Sun, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1276890 · Cited by 10
Can pluripotent/multipotent stem cells reverse Parkinson’s disease progression?
Wu, Y., Meng, X., Cheng, W., Yan, Z., Li, K., Wang, J., Jiang, T., Zhou, F., Wong, K., Zhong, C., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1210447 · Cited by 9
CRISPR/Cas9 applications in gene therapy for primary immunodeficiency diseases
Ravin, S. S. D., & Brault, J. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180157 · Cited by 9
From Basic Biology to Patient Mutational Spectra of GATA2 Haploinsufficiencies: What Are the Mechanisms, Hurdles, and Prospects of Genome Editing for Treatment
Koyunlar, C., & de Pater, E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.602182 · Cited by 10
R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling
Chan, K. Y. Y., Zhang, C., Wong, Y. T. S., Zhang, X., Wang, C. C., Ng, W. H., Fok, S. P., Tang, P. M., Kang, W., Feng, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003307 · Cited by 9
Design of experiments as a decision tool for cell therapy manufacturing
Lee, E., Shah, D., Porteus, M. H., Wright, J. F., & Bacchetta, R. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.01.009 · Cited by 9
Self-citation
Gene Edited T Cell Therapies for Inborn Errors of Immunity
Fox, T. A., Houghton, B. C., & Booth, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.899294 · Cited by 9
YAP and TAZ play a crucial role in human erythrocyte maturation and enucleation
Damkham, N., Lorthongpanich, C., Klaihmon, P., Lueangamornnara, U., Kheolamai, P., Trakarnsanga, K., & Issaragrisil, S. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03166-7 · Cited by 9
CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells
Vlassis, A., Jensen, T. L., Mohr, M., Jędrzejczyk, D., Meng, X., Kovács, G. E., Morera-Gómez, M., Barghetti, A., Abad, S. M., Baumgartner, R. F., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108287 · Cited by 11
A differentiated β-globin gene replacement strategy uses heterologous introns to restore physiological expression
Wallace, K. A., Gerstenberg, T. L., Ennis, C. L., Pérez-Bermejo, J. A., Partridge, J. R., Bandoro, C., Matern, W. M., Andreoletti, G., Krassovsky, K., Kabir, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.036 · Cited by 8
Self-citation
Chemical Modification of Guide RNAs for Improved CRISPR Activity in CD34+ Human Hematopoietic Stem and Progenitor Cells
Shapiro, J., Tovin, A., Iancu, O., Allen, D. G., & Hendel, A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0687-2_3 · Cited by 8
Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase
Boddu, P. C., Gupta, A. K., Kim, J., Neugebauer, K. M., Waldman, T. A., & Pillai, M. M. (2021) · Communications Biology · doi:10.1038/s42003-021-02690-1 · Cited by 8
Engineered human Diamond-Blackfan anemia disease model confirms therapeutic effects of clinically applicable lentiviral vector at single-cell resolution
Liu, Y., Schmiderer, L., Hjort, M., Lang, S., Bremborg, T., Rydström, A., Schambach, A., Larsson, J., & Karlsson, S. (2023) · Haematologica · doi:10.3324/haematol.2022.282068 · Cited by 8

Authors: Bak, R. O., Dever, D. P., & Porteus, M. H.
Affiliations: Stanford Medicine (US)
Corresponding author: Porteus, Matthew H
ORCID: Bak, Rasmus O
Dever, Daniel P
Porteus, Matthew H
Venue: Nature Protocols
Publisher: Springer Science and Business Media LLC
Published: 2018-01-25
Volume: 13
Issue: 2
Pages: 358-376
ISSN: 1750-2799 (ISSN-L)
1754-2189
DOI: 10.1038/nprot.2017.143
PMC: PMC5826598
OpenAlex: W2784423079
Cited by: 319
References: 57
Citations by year: 2026: 23 · 2025: 37 · 2024: 31 · 2023: 47 · 2022: 35 · 2021: 51 · 2020: 50 · 2019: 31 · 2018: 13
FWCI: 12.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Protocols (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5r01ai120766-02)
National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: CRISPR/Cas9 genome editing, hematopoietic stem cells, homologous recombination, AAV6 vector, Cas9 ribonucleoprotein, HSC engraftment, hematopoietic stem and progenitor cells, sickle cell disease, beta-thalassemia, primary immunodeficiency, gene therapy
MeSH terms: Gene Editing, Dependovirus, Animals, Flow Cytometry, Hematopoiesis, Hematopoietic Stem Cells, Humans, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Gene Targeting, Polymorphism, Single Nucleotide, Mice, Homologous Recombination, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CRISPR/Cas9 genome editing in human hematopoietic stem cells.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks